Lung Cancer Therapeutics Market: By Treatment Type, By Disease Type, Small Cell Lung Cancer, By Distribution Channel and Region Forecast 2019-2030

download arrow download arrow Download Free Sample
settings arrow settings arrow email us

Lung Cancer Therapeutics Market Size, Share, Growth, Trends, and Global Industry Analysis: By Treatment Type (Targeted Therapy, Immunotherapy, Chemotherapy), By Disease Type (Non-small Cell Lung Cancer (NSCLC), Small Cell Lung Cancer (SCLC), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies) and Region Forecast 2019-2030

checked icon arrow_drop_down
checked icon Single User License $4400 $3520
checked icon Multiple User License $6600 $5280
checked icon Corporate User License $8900 $7120

Lung Cancer Therapeutics Market size was valued at US$ 18,327.8 million in 2023 and is poised to grow at a CAGR of 13.2% from 2024-2030. The market is growing at a significant CAGR over the forecast timeframe owing to increase in the R&D activities clinical trials for the innovation of new drugs and vaccine for the treatment of lung cancer. Increase in the prevalence of lung cancer (according to world cancer research fund international 2012, lung cancer was the most common cancer which contributes 13% share of the new cancer cases diagnosed) also propelling the market. Acquisitions & mergers, collaborations are the key strategies adopted by the players to gain revenue growth in the market.

Key Developments

  • in November 2015, Eli Lilly and Co. and Merck & Co., Inc. collaborated to evaluate the efficacy and safety of a combination of the Alimta and Keytruda under phase III trials for the treatment of non-small cell lung cancer. Moreover, in January 2016, VisionGate acquired a patent from University of Colorado for Iloprost used in the treatment of lung cancer.   

summary download arrow Download Free Sample

Global Lung Cancer Therapeutics Market Summary

Study Period

2024-2030

Base Year

2023

CAGR

13.2%

Largest Market

North America

Fastest Growing Market

Europe

Lung Cancer Therapeutics Market Dynamics

Lung cancer or lung carcinoma is the disease characterized by the abnormal proliferation of tumour cells in the lung tissues. Lung cancer is classified into 3 types namely lung carcinoid tumour, small cell lung cancer, and non-small cell lung cell cancer. Common symptoms associated with the lung cancer include a cough, weight loss, shortness of breath, and chest pains. Smoking and prolonged use of tobacco are the common risk factors for the lung cancer. Lung cancer can be diagnosed by the biopsy performed by using CT-guidance or bronchoscopy. Lung cancer can be treated by radiotherapy, chemotherapy, and surgery.

Increasing pollution owing to rapid industrialization, a rise in the number of tobacco consumption and smoking population, growing government funding for the R&D activities, and rise in demand for targeted therapies are anticipated to fuel the growth of the market. Moreover, innovation of newer radiotherapies, a launch of low priced generic drugs, and rise in prevalence of non-small cell lung cancer are expected to propel the market over the forecast period. However, stringent regulatory policies, patent expiry of lung cancer therapeutics, poor cancer diagnostics in underdeveloped countries, and adverse effects associated with the treatment might hamper the growth of the market.

Global Lung Cancer Therapeutics Market Segmentation Analysis

Report Benchmarks

Details

Report Study Period

2024-2030

Market Size in 2023

US$ 18,327.8 million

Market CAGR

13.2%

By Drug Class

  • Chemotherapy
  • Targeted therapy

By Disease Type

  • Small cell lung cancer
  • Non-small cell lung cancer
  • Large carcinoid tumour

By End User

  • Hospitals
  • Oncology Clinics
  • Ambulatory surgical centres

By Region

  • North America (U.S., Canada)
  • Europe (Germany, U.K., France, Italy, Russia, Spain, Rest of Europe)
  • Asia-Pacific (China, India, Japan, Australia, Southeast Asia, Rest of Asia Pacific)
  • Latin America (Mexico, Brazil, Argentina, Columbia, Rest of Latin America)
  • Middle East & Africa (GCC, Egypt, Nigeria, South Africa, Rest of Middle East and Africa)

Key Features of the Report

  • The lung cancer therapeutics market report provides granular level information about the market size, regional market share, historic market (2019-2023), and forecast (2024-2030)
  • The report covers in-detail insights about the competitor's overview, company share analysis, key market developments, and their key strategies
  • The report outlines drivers, restraints, unmet needs, and trends that are currently affecting the market
  • The report tracks recent innovations, key developments, and start-up details that are actively working in the market
  • The report provides a plethora of information about market entry strategies, regulatory framework, and reimbursement scenario
  • The report analyses the impact of the socio-political environment through PESTLE Analysis and competition through Porter's Five Force Analysis 

Download Free Sample Report

I accept the Terms and Conditions,Disclaimers, GDPR Policy

Frequently Asked Questions

The global lung cancer therapeutics market size was valued at US$ 18,327.9 million in 2023 and is projected to grow at a CAGR of 13.2% from 2024 to 2030

Rising Pollution due to Rapid Industrialization and Rise in the Number of Smokers

Europe is the fastest-growing for the market

Author image

Author

Muni Kumar Meravath

Muni Kumar Meravath is a seasoned Healthcare Market Research Analyst with over 6 years of experience in the healthc.....

1. Executive Summary
2. Global Lung Cancer Therapeutics Market Introduction
2.1. Global Lung Cancer Therapeutics Market Taxonomy
2.2. Global Lung Cancer Therapeutics Market Definitions
2.2.1. By Treatment Type
2.2.2. By Disease Type
2.2.3. By Distribution Channel
2.2.4. By Region
3. Global Lung Cancer Therapeutics Market Dynamics
3.1. Drivers
3.2. Restraints
3.3. Opportunities/Unmet Needs of the Market
3.4. Trends
3.5. Global Lung Cancer Therapeutics Market Dynamic Factors - Impact Analysis
3.6. Global Lung Cancer Therapeutics Market Competition Landscape
3.7. Epidemiology
4. Global Lung Cancer Therapeutics Market Analysis, 2019-2023 and Forecast, 2024-2030
4.1. Market Analysis, 2019-2023 and Forecast, 2024-2030 (Revenue, USD Mn)
4.2. Year-over-Year (Y-o-Y) Growth Analysis (%)
4.3. Market Opportunity Analysis
5. Global Lung Cancer Therapeutics Market, By Treatment Type, 2019-2023 and Forecast, 2024-2030 (Revenue, USD Mn) 
5.1. Targeted Therapy
5.1.1. Bevacizumab
5.1.1.1. Market Analysis, 2019-2023 and Forecast, 2024-2030 (Revenue, USD Mn)
5.1.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.1.1.3. Market Opportunity Analysis
5.1.2. Dabrafenib/Trametinib
5.1.2.1. Market Analysis, 2019-2023 and Forecast, 2024-2030 (Revenue, USD Mn)
5.1.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.1.2.3. Market Opportunity Analysis
5.1.3. Erlotinib
5.1.3.1. Market Analysis, 2019-2023 and Forecast, 2024-2030 (Revenue, USD Mn)
5.1.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.1.3.3. Market Opportunity Analysis
5.1.4. Osimertinib
5.1.4.1. Market Analysis, 2019-2023 and Forecast, 2024-2030 (Revenue, USD Mn)
5.1.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.1.4.3. Market Opportunity Analysis
5.1.5. Others
5.1.5.1. Market Analysis, 2019-2023 and Forecast, 2024-2030 (Revenue, USD Mn)
5.1.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.1.5.3. Market Opportunity Analysis
5.2. Immunotherapy
5.2.1. Durvalumab
5.2.1.1. Market Analysis, 2019-2023 and Forecast, 2024-2030 (Revenue, USD Mn)
5.2.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.2.1.3. Market Opportunity Analysis
5.2.2. Nivolumab
5.2.2.1. Market Analysis, 2019-2023 and Forecast, 2024-2030 (Revenue, USD Mn)
5.2.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.2.2.3. Market Opportunity Analysis
5.2.3. Atezolizumab
5.2.3.1. Market Analysis, 2019-2023 and Forecast, 2024-2030 (Revenue, USD Mn)
5.2.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.2.3.3. Market Opportunity Analysis
5.2.4. Pembrolizumab
5.2.4.1. Market Analysis, 2019-2023 and Forecast, 2024-2030 (Revenue, USD Mn)
5.2.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.2.4.3. Market Opportunity Analysis
5.3. Chemotherapy
5.3.1. Market Analysis, 2019-2023 and Forecast, 2024-2030 (Revenue, USD Mn)
5.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.3.3. Market Opportunity Analysis
6. Global Lung Cancer Therapeutics Market, By Disease Type, 2019-2023 and Forecast, 2024-2030 (Revenue, USD Mn) 
6.1. Non-small Cell Lung Cancer (NSCLC)
6.1.1. Market Analysis, 2019-2023 and Forecast, 2024-2030 (Revenue, USD Mn)
6.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.1.3. Market Opportunity Analysis
6.2. Small Cell Lung Cancer (SCLC)
6.2.1. Market Analysis, 2019-2023 and Forecast, 2024-2030 (Revenue, USD Mn)
6.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.2.3. Market Opportunity Analysis
7. Global Lung Cancer Therapeutics Market Forecast, By Distribution Channel, 2019-2023 and Forecast, 2024-2030 (Revenue, USD Mn) 
7.1. Hospital Pharmacies
7.1.1. Market Analysis, 2019-2023 and Forecast, 2024-2030 (Revenue, USD Mn)
7.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
7.1.3. Market Opportunity Analysis
7.2. Retail Pharmacies
7.2.1. Market Analysis, 2019-2023 and Forecast, 2024-2030 (Revenue, USD Mn)
7.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
7.2.3. Market Opportunity Analysis
7.3. Online Pharmacies
7.3.1. Market Analysis, 2019-2023 and Forecast, 2024-2030 (Revenue, USD Mn)
7.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
7.3.3. Market Opportunity Analysis
8. Global Lung Cancer Therapeutics Market Forecast, By Region, 2019-2023 and Forecast, 2024-2030 (Revenue, USD Mn) 
8.1. North America
8.1.1. Market Analysis, 2019-2023 and Forecast, 2024-2030 (Revenue, USD Mn)
8.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
8.1.3. Market Opportunity Analysis
8.2. Europe
8.2.1. Market Analysis, 2019-2023 and Forecast, 2024-2030 (Revenue, USD Mn)
8.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
8.2.3. Market Opportunity Analysis
8.3. Asia-Pacific
8.3.1. Market Analysis, 2019-2023 and Forecast, 2024-2030 (Revenue, USD Mn)
8.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
8.3.3. Market Opportunity Analysis
8.4. Latin America
8.4.1. Market Analysis, 2019-2023 and Forecast, 2024-2030 (Revenue, USD Mn)
8.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
8.4.3. Market Opportunity Analysis
8.5. Middle East and Africa
8.5.1. Market Analysis, 2019-2023 and Forecast, 2024-2030 (Revenue, USD Mn)
8.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
8.5.3. Market Opportunity Analysis
8.6. Global Lung Cancer Therapeutics Market - Opportunity Analysis Index, By Treatment Type, By Disease Type, By Distribution Channel and Region, 2024-2030
9. North America Lung Cancer Therapeutics Market Analysis, 2019-2023 and Forecast, 2024-2030 (Revenue, USD Mn) 
9.1. Treatment Type Analysis 2019-2023 and Forecast 2024-2030 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
9.1.1. Targeted Therapy
9.1.1.1. Bevacizumab
9.1.1.2. Dabrafenib/Trametinib
9.1.1.3. Erlotinib
9.1.1.4. Osimertinib
9.1.1.5. Others
9.1.2. Immunotherapy
9.1.2.1. Durvalumab
9.1.2.2. Nivolumab
9.1.2.3. Atezolizumab
9.1.2.4. Pembrolizumab
9.1.3. Chemotherapy
9.2. Disease Type Analysis 2019-2023 and Forecast 2024-2030 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
9.2.1. Non-small Cell Lung Cancer (NSCLC)
9.2.2. Small Cell Lung Cancer (SCLC)
9.3. Distribution Channel Analysis 2019-2023 and Forecast 2024-2030 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
9.3.1. Hospital Pharmacies
9.3.2. Retail Pharmacies
9.3.3. Online Pharmacies
9.4. Country Analysis 2019-2023 and Forecast 2024-2030 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)
9.4.1. USA
9.4.2. Canada
9.5. North America Lung Cancer Therapeutics Market - Opportunity Analysis Index, By Treatment Type, By Disease Type, By Distribution Channel and Country, 2024-2030
9.6. North America Lung Cancer Therapeutics Market Dynamics Trends
10. Europe Lung Cancer Therapeutics Market Analysis, 2019-2023 and Forecast, 2024-2030 (Revenue, USD Mn) 
10.1. Treatment Type Analysis 2019-2023 and Forecast 2024-2030 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
10.1.1. Targeted Therapy
10.1.1.1. Bevacizumab
10.1.1.2. Dabrafenib/Trametinib
10.1.1.3. Erlotinib
10.1.1.4. Osimertinib
10.1.1.5. Others
10.1.2. Immunotherapy
10.1.2.1. Durvalumab
10.1.2.2. Nivolumab
10.1.2.3. Atezolizumab
10.1.2.4. Pembrolizumab
10.1.3. Chemotherapy
10.2. Disease Type Analysis 2019-2023 and Forecast 2024-2030 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
10.2.1. Non-small Cell Lung Cancer (NSCLC)
10.2.2. Small Cell Lung Cancer (SCLC)
10.3. Distribution Channel Analysis 2019-2023 and Forecast 2024-2030 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
10.3.1. Hospital Pharmacies
10.3.2. Retail Pharmacies
10.3.3. Online Pharmacies
10.4. Country Analysis 2019-2023 and Forecast 2024-2030 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)
10.4.1. Germany
10.4.2. UK
10.4.3. France
10.4.4. Spain
10.4.5. Italy
10.4.6. Russia
10.4.7. Rest of Europe
10.5. Europe Lung Cancer Therapeutics Market - Opportunity Analysis Index, By Treatment Type, By Disease Type, By Distribution Channel and Country, 2024-2030
10.6. Europe Lung Cancer Therapeutics Market Dynamics Trends
11. Asia-Pacific Lung Cancer Therapeutics Market Analysis, 2019-2023 and Forecast, 2024-2030 (Revenue, USD Mn) 
11.1. Treatment Type Analysis 2019-2023 and Forecast 2024-2030 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
11.1.1. Targeted Therapy
11.1.1.1. Bevacizumab
11.1.1.2. Dabrafenib/Trametinib
11.1.1.3. Erlotinib
11.1.1.4. Osimertinib
11.1.1.5. Others
11.1.2. Immunotherapy
11.1.2.1. Durvalumab
11.1.2.2. Nivolumab
11.1.2.3. Atezolizumab
11.1.2.4. Pembrolizumab
11.1.3. Chemotherapy
11.2. Disease Type Analysis 2019-2023 and Forecast 2024-2030 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
11.2.1. Non-small Cell Lung Cancer (NSCLC)
11.2.2. Small Cell Lung Cancer (SCLC)
11.3. Distribution Channel Analysis 2019-2023 and Forecast 2024-2030 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
11.3.1. Hospital Pharmacies
11.3.2. Retail Pharmacies
11.3.3. Online Pharmacies
11.4. Country Analysis 2019-2023 and Forecast 2024-2030 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)
11.4.1. China
11.4.2. India
11.4.3. Japan
11.4.4. ASEAN
11.4.5. Australia & New Zealand
11.4.6. Rest of Asia-Pacific
11.5. Asia-Pacific Lung Cancer Therapeutics Market - Opportunity Analysis Index, By Treatment Type, By Disease Type, By Distribution Channel and Country, 2024-2030
11.6. Asia-Pacific Lung Cancer Therapeutics Market Dynamics Trends
12. Latin America Lung Cancer Therapeutics Market Analysis, 2019-2023 and Forecast, 2024-2030 (Revenue, USD Mn) 
12.1. Treatment Type Analysis 2019-2023 and Forecast 2024-2030 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
12.1.1. Targeted Therapy
12.1.1.1. Bevacizumab
12.1.1.2. Dabrafenib/Trametinib
12.1.1.3. Erlotinib
12.1.1.4. Osimertinib
12.1.1.5. Others
12.1.2. Immunotherapy
12.1.2.1. Durvalumab
12.1.2.2. Nivolumab
12.1.2.3. Atezolizumab
12.1.2.4. Pembrolizumab
12.1.3. Chemotherapy
12.2. Disease Type Analysis 2019-2023 and Forecast 2024-2030 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
12.2.1. Non-small Cell Lung Cancer (NSCLC)
12.2.2. Small Cell Lung Cancer (SCLC)
12.3. Distribution Channel Analysis 2019-2023 and Forecast 2024-2030 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
12.3.1. Hospital Pharmacies
12.3.2. Retail Pharmacies
12.3.3. Online Pharmacies
12.4. Country Analysis 2019-2023 and Forecast 2024-2030 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)
12.4.1. Brazil
12.4.2. Mexico
12.4.3. Argentina
12.4.4. Rest of Latin America
12.5. Latin America Lung Cancer Therapeutics Market - Opportunity Analysis Index, By Treatment Type, By Disease Type, By Distribution Channel and Country, 2024-2030
12.6. Latin America Lung Cancer Therapeutics Market Dynamics Trends
13. Middle East and Africa Lung Cancer Therapeutics Market Analysis, 2019-2023 and Forecast, 2024-2030 (Revenue, USD Mn) 
13.1. Treatment Type Analysis 2019-2023 and Forecast 2024-2030 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
13.1.1. Targeted Therapy
13.1.1.1. Bevacizumab
13.1.1.2. Dabrafenib/Trametinib
13.1.1.3. Erlotinib
13.1.1.4. Osimertinib
13.1.1.5. Others
13.1.2. Immunotherapy
13.1.2.1. Durvalumab
13.1.2.2. Nivolumab
13.1.2.3. Atezolizumab
13.1.2.4. Pembrolizumab
13.1.3. Chemotherapy
13.2. Disease Type Analysis 2019-2023 and Forecast 2024-2030 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
13.2.1. Non-small Cell Lung Cancer (NSCLC)
13.2.2. Small Cell Lung Cancer (SCLC)
13.3. Distribution Channel Analysis 2019-2023 and Forecast 2024-2030 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
13.3.1. Hospital Pharmacies
13.3.2. Retail Pharmacies
13.3.3. Online Pharmacies
13.4. Country Analysis 2019-2023 and Forecast 2024-2030 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)
13.4.1. Gulf Cooperation Council (GCC) Countries
13.4.2. Israel
13.4.3. South Africa
13.4.4. Rest of MEA
13.5. MEA Lung Cancer Therapeutics Market - Opportunity Analysis Index, By Treatment Type, By Disease Type, By Distribution Channel and Country, 2024-2030
13.6. MEA Lung Cancer Therapeutics Market Dynamics Trends
14. Competition Landscape 
14.1. Strategic Dashboard of Top Market Players
14.2. Company Profiles (Introduction, Financial Analysis, Offerings, Key Developments, Strategies, and SWOT Analysis)
14.2.1. F. Hoffmann-La Roche Ltd
14.2.2. Eli Lilly and Company
14.2.3. Celgene Corporation
14.2.4. AstraZeneca plc
14.2.5. Pfizer, Inc.
14.2.6. Sanofi SA
14.2.7. Novartis AG
14.2.8. Bristol Myers Squibb
14.2.9. Merck MSD
14.2.10. Millennium Pharmaceuticals, Inc.
15. Research Methodology
16. Key Assumptions and Acronyms

 

Key Market Players

  • Hoffmann-La Roche Ltd
  • Eli Lilly and Company
  • Celgene Corporation
  • AstraZeneca plc
  • Pfizer, Inc.
  • Sanofi SA
  • Novartis AG
  • Bristol Myers Squibb
  •  Merck MSD Millennium Pharmaceuticals, Inc.

Related Industry Reports

T Cell Immunotherapy Market

Poland Non Small Cell Lung Cancer Nsclc Market

Cancer Immunotherapy Market

Non Small Cell Lung Cancer Nsclc Treatment Market